News

XTL and Yeda Strengthen Partnership for SLE Therapy

XTL Biopharmaceuticals Ltd. and Yeda Research and Development Company Ltd. have strengthened their collaboration to develop a new therapy for systemic lupus erythematosus (SLE), called hCDR1. The two companies recently signed an amended agreement altering the development milestones featured in the License Agreement signed…

Extracellular Vesicles Explored as Lupus Biomarkers

A new article published by Spanish researchers focuses on whether extracellular vesicles may be used to detect and monitor systemic lupus erythematosus. The work, titled “Extracellular Vesicles as Biomarkers of Systemic Lupus Erythematosus,“ appeared August 25th in the journal Disease Markers. Systemic lupus erythematosus (sometimes called lupus for short)…

Lupus Foundation of America Announces Recipients of 2015 LIFELINE Grants

The leading organization in the U.S. dedicated to addressing lupus, The Lupus Foundation of America, has just revealed the recipients of five research grants, awarded under the Foundation’s commitment to support lupus-focused researchers in conducting clinical trials necessary to better understanding and eventually curing this life-altering autoimmune disease. “The researchers…

Diffuse Alveolar Haemorrhage Reduces SLE Patients’ Long-term Survival

In a recent study entitled “Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival” researchers performed the first study investigating the risk factors for diffuse alveolar haemorrhage in systemic lupus erythematosus and how it impacts patients’ therapy responses and outcomes. The study was published…